‘Off-the-shelf’ CAR-Ts have an important role to play – but are they ready for prime time?
Allogeneic CAR-Ts could serve an important niche - particularly for patients who can't receive autologous CAR-Ts - but the earliness of the data makes conclusions tough to draw.